New drug combo aims to wipe out hidden cancer cells in blood cancer patients
NCT ID NCT06910124
Summary
This study is testing whether adding a new drug called linvoseltamab to standard maintenance therapy can help eliminate any remaining multiple myeloma cells in patients' bodies. The research aims to help patients achieve and maintain 'minimal residual disease negative' status, meaning no detectable cancer cells, and extend the time their disease stays under control. The trial includes 32 adults with newly diagnosed multiple myeloma who have already received initial treatment and are on maintenance therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.